These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17295000)

  • 1. Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells.
    Matsui T; Yamagishi S; Nakamura K; Inoue H
    J Int Med Res; 2006; 34(6):671-5. PubMed ID: 17295000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
    Nakamura K; Yamagishi S; Inoue H
    Med Hypotheses; 2005; 65(1):155-7. PubMed ID: 15893134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties.
    Yamagishi S; Inagaki Y; Nakamura K; Imaizumi T
    J Cardiovasc Pharmacol; 2004 May; 43(5):724-30. PubMed ID: 15071361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species.
    Naito Y; Shimozawa M; Manabe H; Nakabe N; Katada K; Kokura S; Yoshida N; Ichikawa H; Kon T; Yoshikawa T
    Eur J Pharmacol; 2006 Sep; 546(1-3):11-8. PubMed ID: 16919261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation.
    Yamagishi S; Inagaki Y; Kikuchi S
    Drugs Exp Clin Res; 2003; 29(4):147-52. PubMed ID: 15018305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition.
    Takahashi K; Shimokado K; Yoshida M
    Eur J Pharmacol; 2006 Dec; 552(1-3):162-9. PubMed ID: 17067573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.
    Matsui T; Yamagishi S; Nakamura K; Kikuchi S; Inoue H
    Drugs Exp Clin Res; 2005; 31(5-6):215-9. PubMed ID: 16425978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates.
    Nakano K; Egashira K; Tada H; Kohjimoto Y; Hirouchi Y; Kitajima S; Endo Y; Li XH; Sunagawa K
    J Hypertens; 2006 Sep; 24(9):1881-9. PubMed ID: 16915039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antioxidant effect of a new calcium antagonist, azelnidipine, in cultured human arterial endothelial cells.
    Shinomiya K; Mizushige K; Fukunaga M; Masugata H; Ohmori K; Kohno M; Senda S
    J Int Med Res; 2004; 32(2):170-5. PubMed ID: 15080021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nifedipine inhibits tumor necrosis factor-alpha-induced upregulation of monocyte chemoattractant protein-1 mRNA levels by suppressing CD40 expression in endothelial cells.
    Yamagishi S; Takeuchi M
    Drugs Exp Clin Res; 2005; 31(1):13-7. PubMed ID: 15921025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects.
    Kurobe H; Matsuoka Y; Hirata Y; Sugasawa N; Maxfield MW; Sata M; Kitagawa T
    J Thorac Cardiovasc Surg; 2013 Dec; 146(6):1501-8. PubMed ID: 23535154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells.
    Ma J; Kishida S; Wang GQ; Meguro K; Imuta H; Oonuma H; Iida H; Jo T; Takano H; Morita T; Nagai R; Nakajima T
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):314-21. PubMed ID: 16495772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice.
    Nakano K; Egashira K; Ohtani K; Gang Z; Iwata E; Miyagawa M; Sunagawa K
    Atherosclerosis; 2008 Jan; 196(1):172-179. PubMed ID: 17481639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bay w 9798, a dihydropyridine structurally related to nifedipine with no calcium channel-blocking properties, inhibits tumour necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
    Matsui T; Yamagishi S; Nakamura K; Inoue H
    J Int Med Res; 2007; 35(6):886-91. PubMed ID: 18084847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
    Jinno T; Iwai M; Li Z; Li JM; Liu HW; Cui TX; Rakugi H; Ogihara T; Horiuchi M
    Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine reducing effect of azelnidipine in human peripheral blood mononuclear cells.
    Miura R; Nakamura K; Miura D; Miura A; Kajiya M; Hisamatsu K; Nagase S; Morita H; Kusano KF; Matsubara H; Ohe T; Ito H
    Biol Pharm Bull; 2010; 33(7):1148-51. PubMed ID: 20606305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
    Kimura Y; Hirooka Y; Sagara Y; Sunagawa K
    Clin Exp Hypertens; 2007 Jan; 29(1):13-21. PubMed ID: 17190727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of benidipine, a dihydropyridine-Ca2+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells.
    Matsubara M; Hasegawa K
    Eur J Pharmacol; 2004 Sep; 498(1-3):303-14. PubMed ID: 15364009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.
    Ohyama T; Sato K; Kishimoto K; Yamazaki Y; Horiguchi N; Ichikawa T; Kakizaki S; Takagi H; Izumi T; Mori M
    Br J Pharmacol; 2012 Feb; 165(4b):1173-87. PubMed ID: 21790536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azelnidipine Inhibits the Differentiation and Activation of THP-1 Macrophages through the L-Type Calcium Channel.
    Komoda H; Shiraki A; Oyama JI; Nishikido T; Node K
    J Atheroscler Thromb; 2018 Aug; 25(8):690-697. PubMed ID: 29398679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.